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Background. Although consensus-based guidelines support noninvasive stress testing prior
to orthotopic liver transplantation (OLT), the optimal screening strategy for assessment of
coronary artery disease in patients with end-stage liver disease (ESLD) is unclear. This study
sought to determine the relative predictive value of coronary risk factors, functional capacity,
and single photon emission computed tomography (SPECT) on major adverse cardiovascular
events and all-cause mortality in liver transplantation candidates.
Methods. Prior to listing for transplantation, 404 consecutiveESLDpatients were referred to a
University hospital for cardiovascular (CV) risk stratification. All subjects met at least one of the
following criteria: inability to perform> 4METsbyhistory (62%), insulin-treated diabetesmellitus
(53%), serum creatinine > 1.72mg/dL (8%), history ofMI, PCI orCABG (5%), stable angina (3%),
cerebrovascular disease (1%), peripheral vascular disease (1%). Subjects underwent Technetium-
99m SPECT with multislice coronary artery calcium scoring (CACS) using exercise treadmill or
standard adenosine stress in those unable to achieve 85% maximal heart rate (Siemens Symbia
T16). Abnormal perfusion was defined as a summed stress score (SSS) ‡ 4.
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Results. Of the 404 patients, 158 (age 59 ± 9 years; male 68%) subsequently underwent
transplantation and were included in the primary analysis. Of those, 50 (32%) died after a mean
duration follow-up of 5.4 years (maximal 10.9 years). Most deaths (78%) were attributed to
noncardiovascular causes (malignancy, sepsis, renal failure). Of the 32 subjects with abnormal
perfusion (20%), nine (6%) had a high-risk perfusion abnormality defined as a total perfusion
defect size (PDS) ‡ 15% and/or an ischemic PDS ‡ 10%. Kaplan–Meier survival curves
demonstrated abnormal perfusion was associated with increased CV mortality (generalized
Wilcoxon, P = 0.014) but not all-cause death. Subjects with both abnormal perfusion and an
inability to exercise > 4METs had the lowest survival from all-cause death (P = 0.038). Abnormal
perfusionwas a strong independent predictor of CV death (adjustedHR4.2; 95%CI 1.4 to 12.3;P
= 0.019) and MACE (adjusted HR 7.7; 95% CI 1.4 to 42.4; P = 0.018) in a multivariate Cox
regression model that included age, sex, diabetes, smoking and the ability to exercise > 4 METs.
There was no association between CACS and the extent of perfusion abnormality, nor with
outcomes.
Conclusions. Most deaths following OLT are noncardiovascular. Nonetheless, abnormal
perfusion is prevalent in this high-risk population and a stronger predictor of cardiovascular
morbidity and mortality than functional status. A combined assessment of functional status and
myocardial perfusion identifies those at highest risk of all-cause death. (Exercise Capacity and
Single Photon Emission Computed Tomography in Liver Transplantation Candidates
[ExSPECT]; ClinicalTrials.gov Identifier: NCT03864497). (J Nucl Cardiol 2020)
Key Words: SPECT Æ diagnostic and prognostic application Æ outcomes research Æ exercise
testing Æ vasodilators
Abbreviations
CAD Coronary artery disease
CACS Coronary artery calcium score
CV Cardiovascular
ESLD End-stage liver disease
METs Metabolic equivalents
OLT Orthotopic liver transplantation
PDS Perfusion defect size
SPECT Single photon emission computed
tomography
SSS Summed stress score
INTRODUCTION
There is ongoing debate over the optimal screening
method for coronary artery disease (CAD) in patients
with end-stage liver disease (ESLD) being considered
for transplantation. Although screening is widely prac-
ticed, no current strategy has yet been shown to improve
outcomes in these subjects. In 2012, the American Heart
Association and American College of Cardiology
(AHA/ACC) published guidelines suggesting that
regardless of functional status, the presence of C 3
cardiovascular (CV) risk factors (age C 60 years,
diabetes mellitus, smoking, hypertension, dyslipidemia,
left ventricular hypertrophy) should prompt screening of
asymptomatic candidates under consideration for ortho-
topic liver transplantation (OLT).1 This was a
consensus-based recommendation (Class IIb, Level of
Evidence C), which reflects the limited quality of data
evaluating the efficacy of perioperative risk stratification
in this population. Those retrospective observational
studies that are available report low sensitivity and
specificity for both dobutamine stress echocardiography
(DSE)2-5 and single photon emission computed tomog-
raphy (SPECT) imaging in OLT candidates.6,7 This may
in part, relate to the high resting myocardial blood flows
associated with cirrhotic liver disease, which may lend
itself poorly to pharmacological vasodilator stress.6,8
Nonetheless, in 2013 the American Association for the
Study of Liver Diseases and American Society of
Transplantation guidelines proposed DSE as ‘‘an effec-
tive screening test’’ in OLT candidates.9,10 In reality,
most liver transplant centers tailor their choice of
noninvasive stress imaging according to local expertise.
This practice is supported by the latest data suggesting
SPECT has equivalent efficacy compared with DSE in
the identification of clinically significant CAD,11 and in
keeping with an ACC Appropriate Use Criteria Task
Force Report, which rated both modalities ‘‘appropri-
ate’’ for ESLD subjects with poor functional capacity (\
4 METs).12
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The AHA/ACC recommendation to perform nonin-
vasive screening in high-risk OLT candidates is
supported by the finding that obstructive CAD on
invasive angiography is more common in subjects
referred with conventional risk factors.13 Despite this
observation, traditional CV risk factors tend to perform
poorly at predicting increased CV event rates in the
ESLD population.14-17 In a retrospective analysis of 413
subjects undergoing liver transplant surgery, despite
including all conventional CV factors in multivariate
modeling, only a history of CAD or stroke were
significant predictors of adverse cardiac outcomes at
30 days.14 In contrast, cardiopulmonary exercise testing
(CPET) with measurement of estimated METs or
maximum aerobic capacity, may offer more useful
prognostic information in OLT candidates.18 Reduced
aerobic capacity has been associated with worse out-
comes following liver transplantation, although follow-
up was limited to 9019 and 100 days.20
Controversy over whether SPECT imaging offers
clinical utility in ESLD has been fueled by the conflict-
ing reports on its accuracy to diagnose CAD in this
setting.6,7,11,21 Moreover, there are no studies examining
whether SPECT imaging provides any incremental
prognostic value beyond functional testing in this
high-risk cohort. We sought to determine, therefore,
the relative importance of CV risk factors, functional
capacity and SPECT perfusion as independent predictors
of adverse outcome in OLT candidates.
METHODS
Population
ExSPECT (Exercise Capacity and Single Photon
Emission Computed Tomography in Liver Transplanta-
tion Candidates) was an observational cohort study,
including consecutive ESLD patients referred for car-
diac evaluation between September 2007 and June 2018,
prior to consideration for liver transplantation. In
accordance with local guidelines, subjects were referred
for noninvasive CV risk assessment if they fulfilled any
of the following criteria: inability to perform[4 METs
by history, insulin-treated diabetes mellitus, serum
creatinine[ 1.72 mg/dl, history of MI, PCI or CABG,
stable angina, cerebrovascular disease, or peripheral
vascular disease. The conduct and reporting of this study
was in line with the principles of the Declaration of
Helsinki and guided by the STROBE (Strengthening the
Reporting of Observational Studies in Epidemiology)
Statement.22 The study was approved by the University
Hospital Birmingham NHS Divisional Clinical Quality
Group (CARMS-14536) and was registered with Clin-
icalTrials.gov (NCT03864497).
Clinical Data
The data that support the findings of this study are
available from the corresponding author upon reason-
able request. Demographic and anthropometric data
were prospectively entered onto the patient’s electronic
record. In addition, a standardized pre-scan clinical
assessment was carried out including a detailed inter-
view which elicited patient symptoms, CV risk factors,
previous CV events, the cause for liver disease, the
model for end-stage liver disease (MELD) score and
medication history. Routine hematology and biochem-
istry indices at the time of the SPECT/CT imaging were
also recorded. Diabetes mellitus (DM) was defined as a
fasting glucose [ 126 mg/dL, previous history of
diabetes mellitus, or currently receiving hypoglycemic
treatment. Hypertension was defined as an office blood
pressure [ 140/90 mmHg, or currently taking antihy-
pertensive medication. Hypercholesterolemia was
defined as a serum cholesterol of [ 193 mg/dL, or
currently taking lipid reduction therapy. History of CV
disease included known coronary artery disease (my-
ocardial infarction, previous percutaneous or surgical
revascularization), heart failure, stroke, and peripheral
vascular disease. Significant family history of CV
disease was defined as a first degree relative with a
history of myocardial infarction or ischemic stroke aged
younger than 55 years in men and younger than 65 years
in women.
SPECT/CT
Patients were asked to discontinue b-blockers, rate-
limiting calcium channel blockers, and caffeine products
24 hours before testing, and nitrate compounds were
discontinued more than 6 hours before testing. All
participants underwent 2-day stress-rest Technetium-
99m SPECT imaging (Symbia T16, Siemens, Erlangen,
Germany). Those patients capable of exercise underwent
treadmill stress. Standard adenosine stress was per-
formed (140 lg/kg/min for 6 minutes) in those subjects
unable to exercise or unable to achieve 85% of age-
predicted maximal heart rate. Hemodynamic response to
adenosine was assessed by comparing hemodynamics at
rest and after 3 to 4 minutes of adenosine infusion,
immediately prior to radiotracer administration. An
inadequate response was defined as a decrease in
systolic blood pressure of \ 10 mmHg or heart rate
increase\10 beats/min with adenosine infusion.23 CT-
based attenuation correction was performed in all
patients during reconstruction of the SPECT data.
Multislice coronary artery calcium scoring (CACS)
was also performed as routine in subjects without a
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history of myocardial infarction or coronary
revascularization.
SPECT myocardial perfusion images were visually
analyzed by two experienced observers (R.P.S. and
B.H.) blinded to outcome variables (Hermes Medical
Solutions, Quantitative Perfusion SPECT, Stockholm,
Sweden). In addition to examination of raw images in
cine mode, both nonattenuated and attenuated images
were reviewed and a report was produced consistent
with recommendations from the American Society of
Nuclear Cardiology Imaging Guidelines for Nuclear
Cardiology Procedures.24 Short-axis and vertical long-
axis tomograms were divided into 17 segments for each
study,24 and segmental tracer uptake was evaluated
using a validated semi-quantitative 5-point scoring
system (0, normal; 1, equivocal; 2, moderate; 3, severe
reduction of radioisotope uptake; and 4, absence of
detectable tracer uptake).25 The summed stress and rest
scores were obtained by adding the scores of the 17
segments of the respective images. The sum of the
differences between each of the 17 segments from these
images was defined as the summed difference score,
representing the amount of ischemia. These indices were
converted to the percentage of total myocardium
involved with stress, ischemic, or fixed defects by
dividing the summed scores by 68 (the maximum
potential score = 4 9 17), and multiplying by 100. The
presence of abnormal perfusion was defined as a
summed stress score (SSS) of 4 or greater.26 A stress-
induced total perfusion defect size (PDS)[ 15% or an
ischemic PDS [ 10% defined high risk for cardiac
events.27 Cardiac volumes and left ventricular ejection
fraction were calculated from the gated SPECT images
(QGS 2012, Cedars-Sinai Medical Center, Los Angeles,
CA, USA).
The CACS was calculated according to Agatston
et al.28 by the same two independent observers in
subjects without known coronary artery disease blinded
to outcome data. Lesions were manually traced on CT
images before semiautomatic quantification derived
vessel-specific scores were summated to yield the total
CACS (SyngoVia, Leonardo, Siemens Medical Solu-
tions, Forchheim, Germany). Minimal, mild, moderate,
and severe coronary calcification were defined as Agat-
ston scores of 0 to 10 U, 11 to 100 U, 101 to 400 U and
[ 400 U, respectively.27,29
Exercise Stress Testing
Exercise treadmill testing (ETT) was carried out
according to standard protocols (Bruce and modified
Bruce) aiming to achieve [ 85% of age-predicted
maximal heart rate with a goal test duration of between 8
and 12 minutes.30 During exercise, data on symptoms,
rhythm, heart rate, blood pressure (by indirect arm-cuff
sphygmomanometry), and estimated workload in meta-
bolic equivalents (METs) were recorded and entered
prospectively into the patient electronic record. A
positive test was defined as one showing 1mm of ST
segment elevation or depression (of any morphology and
in any lead except aVR) 80 msec after the end of the
QRS complex any time after exercise was begun. A
negative test was one without this degree of ST segment
change and in which the patient achieved 85% of the
maximum predicted heart rate for his age. All other tests
were considered indeterminate.31 To improve the esti-
mated accuracy of exercise capacity, patients were
explicitly told not to lean on handrails during exercise.
Estimated functional capacity in METs was estimated
from the total time completed in the final stage32; a MET
is a measure of oxygen consumption defined as 1 kcal/
kg/hour (equivalent to 3.5 ml of Oxygen/kg/min), which
represents basal, rest metabolic needs. The Bruce
protocol formula was used for estimating maximal
oxygen uptake (VO2 max).33
Coronary Angiography
Those patients with a high-risk perfusion abnor-
mality on SPECT MPI were considered for invasive
coronary angiography. The decision to proceed to
angiography ?/- invasive revascularization was made
by the individual treating physician after each case was
discussed in a dedicated multidisciplinary team meeting.
End Points
The primary outcome measure was cardiovascular
death. Major adverse cardiovascular events (MACE) and
all-cause mortality were examined separately as sec-
ondary outcomes. Major adverse cardiovascular events
were defined as a composite endpoint of cardiac death,
nonfatal myocardial infarction (MI), malignant arrhyth-
mia, ischemic stroke, or hospitalization for congestive
heart failure. Myocardial infarction was defined as a
clinical (or pathologic) event caused by myocardial
ischemia where there is evidence of myocardial injury or
necrosis as defined by a rise and/or fall of cardiac
biomarkers in the presence of typical symptoms or
electrocardiographic changes, or imaging evidence of
new loss of viable myocardium or new regional wall
motion abnormality.34 For the primary analysis, patients
who did not undergo liver transplant surgery during the
study period were identified and excluded from follow-
up because of the strong mortality benefit associated
with OLT in cirrhotic liver disease (see Data Supple-
ment for outcome analysis including all consecutive
subjects). Similarly, patients who had revascularization
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procedures within 90 days of an abnormal baseline
SPECT imaging study were excluded to remove out-
comes driven temporally by this result.35
Every patient in the NHS has a unique identifier
which enables outcomes to be tracked using the Hospital
Episodes Statistics (HES) Database, an administrative
data warehouse containing admissions to all National
Health Service hospitals in England.36 It contains
detailed records relating to individual patient treatments,
with data extraction facilitated using codes on procedu-
ral classifications (Office of Population Censuses and
Surveys Classification of Interventions and Procedures,
4th revision (OPCS-4)) and medical classifications
(World Health Organization International Classification
of Disease, 10th revision (ICD-10)).37,38 With regard to
outcome analysis, HES data alone have the limitation of
only capturing deaths occurring in a hospital setting. To
obtain the complete mortality list, the study cohort was
also cross-referenced with mortality data from the Office
for National Statistics (ONS), which collects informa-
tion on all registered deaths in the UK.
An endpoint committee consisting of a cardiologist
(W.E.M) and a hepatologist (J.F) adjudicated all out-
comes by consensus. Outcomes were further verified by
cross-referencing with individual hospital case notes
held electronically. The endpoint committee was blinded
to all clinical and imaging results.
Statistics
Statistical analyses were performed with SPSS
version 25 (IBM, Armonk, New York, US). Data are
expressed as mean ± SD, median (interquartile range),
or frequency (%), unless otherwise stated. The normality
of distribution for continuous variables was determined
using normality plots and the Kolmogorov-Smirnov test.
Baseline characteristics of the population were exam-
ined by SPECT results. The Mann-Whitney U test was
used to compare continuous nonparametric data. The
Kruskal-Wallis analysis of variance was used to identify
significant differences in central tendencies of continu-
ously scaled variables between groups. Contingency
table analysis was performed using Chi-square or
Fisher’s exact tests where appropriate.
Annualized mortality rates are expressed as the
number of patients having cardiovascular or all-cause
death as a proportion of the number of patients at risk
divided by the number of patient-years follow-up.
Kaplan–Meier analysis of outcomes was based on
discrete SPECT and exercise capacity categories. The
date of the imaging test was used as time zero. Two-
sided generalized Wilcoxon tests were used to determine
significance. Multivariate Cox proportional hazards
models were used to identify the association between
time-to-event and baseline clinical characteristics, esti-
mated METs, and SPECT results. The change in the
global Chi-square statistic was calculated to determine
the incremental prognostic value of clinical, exercise
and SPECT data; the Chi-square of the model was
calculated from the log likelihood ratio. A P value\0.05
was considered statistically significant for all analyses.
RESULTS
Of the 404 patients with ESLD undergoing SPECT
imaging between September 2007 and June 2018, 160
subjects subsequently underwent OLT. Reasons for
patients not proceeding to OLT included compensated
cirrhosis, extra-hepatic malignancy, hepatopulmonary
syndrome, hepatorenal syndrome, severe obesity, mal-
nutrition, active substance abuse, and psychosocial
issues. Two patients without a prior diagnosis of
coronary atheroma were excluded after undergoing
early revascularization driven by the SPECT imaging
demonstrating an ischemic PDS C 10%. This resulted in
158 subjects available for inclusion in the present
analysis (Figure 1). The demographics and outcomes for
all consecutive patients (n = 404) are provided in the
Data Supplement.
The baseline demographics and clinical character-
istics of the study cohort are summarized in Table 1.
Mean age was 57 years, 70% were male, 50% were
diabetic, and 11% were hypertensive. Almost all patients
were asymptomatic (97%). Table 2 summarizes the
results of the functional assessment and imaging char-
acteristics for all included subjects. The median time
between SPECT imaging and liver transplant was 4
months (IQR 2.1 to 9.0)
SPECT/CT
Abnormal perfusion was identified in 32 of the 158
patients (20%). Of those, 9 subjects (6%) had a high-risk
perfusion abnormality, which was associated with a
lower left ventricular ejection fraction on gated analysis
(Table 3). There was no difference in the mean number
of cardiac risk factors between subjects with a normal
SPECT result and those with abnormal perfusion or a
high-risk perfusion abnormality. There was, however, a
graded association between the size of perfusion defect
and the proportion of subjects with hypercholes-
terolemia. Subjects with abnormal perfusion on
SPECT showed a trend toward higher CAC scores but
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SPECT/CT in end-stage liver disease
this result did not reach significance (P = 0.087,
Table 3).
The relationship between CACS and SPECT results
is displayed in Figure 2. Most patients had zero,
minimal or mild CAC (71%). The majority of those
with minimal CACS (90%) had normal perfusion,
although 4 subjects (10%) with minimal CACS did
demonstrate a high-risk SPECT profile based on a stress-
induced total PDS C 15%. Those subjects with at least
moderate CAC (29%) were more likely to have diabetes
(Chi-square = 4.2, P = 0.04) although there was no
association between increasing CACS and any other
traditional risk factor.
Exercise
There was no significant association between the
ability to perform treadmill exercise and the likelihood
of having a perfusion defect or the CACS severity. In the
77 patients (49%) who underwent exercise stress, there
was no association between the number of METS
achieved and the likelihood of an abnormal perfusion
result (Table 3). There was, however, a weak correlation
between increasing CACS and reduced METS (q = -
0.45, P = 0.046).
Coronary Angiography
Of the 9 subjects with a high-risk perfusion abnor-
mality by SPECT (total PDS C 15%), 6 patients had an
ischemic PDS C 10%. Of those, 3 subjects proceeded to
invasive coronary angiography. Subsequently, 2 patients
were diagnosed with nonobstructive coronary disease
and 1 patient with obstructive coronary disease.
Outcomes
There were a total of 50 deaths (32%) after a mean
duration of 5.4 years (maximal follow-up 10.9 years),
and most (78%) were attributed to noncardiovascular
causes (Table 4). Kaplan–Meier survival curves demon-
strate abnormal perfusion was associated with increased
CV mortality (generalized Wilcoxon, P = 0.014) but not
all-cause death (Figure 3). Although there was a trend
toward increased CV mortality in those patients with
impaired functional status (Figure 4), this result did not
reach statistical significance (generalized Wilcoxon, P =
0.24). Similarly, on Kaplan–Meier survival analysis, for
patients that underwent adenosine stress (i.e., those
patients unable to perform treadmill exercise) there was
a trend toward increased CV and all-cause mortality but
Figure 1. Study consort diagram. Abbreviations: OLT, orthotopic liver transplantation; PCI,
percutaneous coronary intervention; CABG, coronary artery bypass graft surgery.
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Table 1. Baseline demographics and clinical characteristics for study cohort
Variable N = 158
Age (years) 56.6 ± 8.9






Body mass index (kg/m2) 29.9 ± 6.1
Etiology of end-stage liver disease
Alcohol 36 (23%)
Hepatitis B 1 (1%)
Hepatitis C 21 (17%)
Nonalcoholic steatohepatitis 29 (19%)
Primary biliary cirrhosis 10 (6%)
Cryptogenic 2 (1%)
Autoimmune 2 (1%)
Alpha-1-antitrypsin deficiency 2 (1%)
Other 35 (29%)





Current smoker 28 (18%)
Family history of CAD 2 (1%)
Number of cardiac risk factors 1.7 ± 1.0
Symptomatic chest pain 2 (1%)
Typical angina/atypical or noncardiac 1 (1%)/1 (1%)
History of revascularization (PCI or CABG) 5 (3%)




ACE inhibitor/angiotensin receptor blocker 15 (9%)
Calcium channel blocker 2 (1%)
Loop diuretic 40 (25%)
Mineralocorticoid receptor antagonist 50 (32%)
Statin 35 (22%)
Insulin 77 (49%)
Hemoglobin (g/L) 117 (105-129)
Total cholesterol (mg/dL) 157 ± 54
INR 1.36 ± 0.33
Creatinine (mg/dL) 0.90 (0.75-1.15)
Data are number (%), mean ± SD or median (IQR)
aOn Insulin or oral hypoglycemic therapy
ACE, angiotensin converting enzyme; CABG, coronary artery bypass graft surgery; CAD, coronary artery disease; IQR, interquartile
range; PCI, percutaneous coronary intervention
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this association did not reach significance (P = 0.398 and
P = 0.791, respectively, Figure 4). There was, however,
incremental predictive value when integrating the results
of functional testing and SPECT imaging (Figures 5, 6,
7); subjects with both abnormal perfusion and an
inability to exercise[ 4 METs had elevated cardiovas-
cular and all-cause mortality (generalized Wilcoxon, P =
0.004 and P = 0.038, respectively).
Abnormal perfusion was an independent predictor
of CV death albeit with wide confidence intervals
(Table 5; adjusted HR 4.2; 95% CI 1.4 to 27.3; P=0.019)
and MACE (adjusted HR 7.7; 95% CI 1.4 to 42.4; P =
0.018) in a multivariate Cox regression model that
included age, sex, diabetes, smoking and the ability to
exercise[4 METs. There was no significant association
between CACS and adverse outcomes. One patient with
a minimal CACS suffered a sudden cardiac death.
In subjects with abnormal perfusion by SPECT
(SSS C 4), the annualized cardiovascular death rate was
2.6% versus 1.0% in those with normal perfusion (P\
0.001). Subjects with abnormal perfusion and who were
unable to exercise C 4 METs experienced the highest
annualized cardiovascular and all-cause mortality rates
(3.9% and 28.3%, respectively; Figure 6). Only 7 out of
the 126 subjects (5.5%) with normal SPECT perfusion
suffered a CV death after a mean follow-up of 5.4 years;
four of these subjects underwent adenosine stress and 3
had exercise stress testing.
Figure 7 depicts the incremental value of stress
SPECT results over clinical data to predict cardiovas-
cular death by global Chi-square analysis. There was a
significant improvement in risk prediction with the
addition of abnormal perfusion on SPECT to clinical
information and exercise capacity (Chi-square change =
4.7, P = 0.04).
DISCUSSION
In the longest follow-up survival study of OLT
candidates undergoing noninvasive stress imaging to
date, we have shown that abnormal perfusion is common
in this high-risk population (20%) and is a stronger
predictor of cardiovascular morbidity and mortality than
functional status. The addition of abnormal perfusion to
coronary risk factors and exercise capacity provides
incremental prognostic utility for the prediction of CV
death. Nonetheless, most subjects die from non-CV
causes and a combined assessment of functional status
and myocardial perfusion identifies those at highest risk
of all-cause mortality. Cardiorespiratory fitness (as
defined by estimated METs) and abnormal perfusion
(as determined by SPECT); therefore, both appear to be
important predictors of adverse long-term outcomes
post-liver transplantation.
There are limited quality studies guiding clinicians
on risk stratification in the perioperative period (at the
time of transplantation and in the postoperative period
out to 6 months) but even less data addressing risk
beyond 6 months, when the patient is thought to be more
commonly on a reduced immunosuppression regime. To
date, almost all follow-up studies involving noninvasive
stress testing for risk stratification prior to OLT have
Table 2. Functional assessment and imaging characteristics for study cohort
Variable N = 158
Exercise treadmill stress 77 (49%)
METs achieveda 6.3 ± 2.4
Peak VO2 achieved (ml/kg/min)a 22.2 ± 8.4
Positive/indeterminate/negativea 2 (3%) / 13 (17%) / 61 (80%)
LV ejection fraction, % 60.9 ± 9.7
Abnormal SPECTb 32 (20%)
Summed stress score C 9 9 (6%)
Total PDS C 15% 9 (6%)
Ischemic PDS C 10% 6 (4%)
CACS, Agatston units (IQR)c 11 (0–119)
Data are number (%), mean ± SD or median (IQR)
aIn the 77 patients that were capable of exercise treadmill exercise stress
bDefined as summed stress score of 4 or more
cIn the 84 patients for whom data were available
CACS, coronary artery calcium score; LV, left ventricular; METs, metabolic equivalents; PDS, perfusion defect size; SPECT, single
photon emission computed tomography; VO2, oxygen uptake
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focused on perioperative outcomes.5,11,14,19,20,39 One of
the major advantages of the current study is its ability to
inform clinicians on intermediate and long-term out-
comes. This is particularly relevant because liver grafts
have become an increasingly scarce commodity; clini-
cians, therefore, have an important duty to ensure that
graft survival is not limited by premature CV death.
Based on the current study, the incorporation of com-
bined functional and perfusion data into pre-operative
risk stratification should help facilitate appropriate
resource allocation, which in turn may lead to better
overall long-term outcomes for patients with ESLD.
In our institution, SPECT imaging is reserved for
high-risk candidates; only 49% of subjects were capable
of treadmill exercise stress and 50% were diabetic.
Using this pre-op risk stratification strategy, the 5-year
survival for this specific cohort was 68%. Taking into
account the high-risk baseline profile of this selected
population, this figure compares favorably with the
unadjusted 5-year survival rate for adult liver transplant
recipients (72%) reported by the U.S. Organ Procure-
ment and Transplantation Network.40 In keeping with a
study from Zoghbi et al.,41 which included 82 patients
undergoing SPECT, most of our patients suffered a non-
CV death, although the frequency of abnormal perfusion
was notably higher in our cohort (20% vs. 9%). This
finding might be explained by the higher proportion of
males (70% vs. 63%) and active smokers (18% vs.
12%), as well as a higher prevalence of diabetes mellitus
(50% vs. 16%).
A small proportion of subjects with normal SPECT
perfusion (5.5%) suffered a CV death after an extended
period of follow-up (mean 5.4 years), although only one
occurred within the first 6 months. It is well recognized
that the highest risk period is often at the time of donor
liver reperfusion when unstable arrhythmia can be
induced.5,17,42 It is conceivable that perioperative CV
events might occur in the absence of ischemia in patients
with lactatemia, acidosis, hypoxia, hypotension, or
electrolyte disturbances, which may predispose to
acquired electrocardiogram abnormalities such as a
prolonged QT interval. Despite prior concerns about
the sensitivity of vasodilator stress SPECT testing in
patients with cirrhotic liver disease and high resting
myocardial blood flows,6,8 the current data suggest it has
the ability to detect prognostically important CV disease
in the short- and intermediate-term.
There was incremental prognostic utility from
adding SPECT perfusion data to traditional coronary
risk factors and these findings contrast with a recent
report suggesting a simple assessment of traditional CV
risk factors was equivalent to SPECT imaging in its
diagnostic ability to predict significant coronary artery
disease.7 In our cohort, smoking was the only conven-
tional risk factor independently associated with reduced
CV survival. Roughly one half of this cohort constituted
asymptomatic diabetic patients but in contrast to abnor-
mal perfusion, the presence of diabetes was not an
independent predictor of premature CV death. This
finding needs to be taken into consideration with the
results of the DIAD study,43 which showed that screen-
ing asymptomatic diabetic with SPECT MPI did not
Figure 2. Relation between CACS severity and stress SPECT
results (n = 84). The percentage of subjects with a normal
SPECT result was highest in those with minimal CACS (P\
0.001). A 4 9 2 contingency analysis was performed using a
two-tailed Fisher’s exact test to determine significance.
Table 4. Follow-up (N = 158)






Recurrent liver disease 6
Other 1
Major adverse cardiac events 19 (12%)
Cardiovascular death 11
Fatal myocardial infarction 4
Sudden cardiac death 4
Ischemic stroke 3
Nonfatal myocardial infarction 1
Revascularizationa 2
Aborted sudden cardiac death 2
Nonfatal ischemic stroke 2
Congestive heart failure 1
Values are N (%) or N
aLate revascularization[90 days after the SPECT/CT imaging
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confer an improvement in CV outcomes over a similar
follow-up period (4.8 years).
In the general population, there is a well-recognized
inverse association between functional status and mor-
tality, independent of age44, sex45,46, and ethnicity47. In
a recent cohort study including 122,007 patients under-
going treadmill testing, the increase in all-cause
mortality associated with reduced cardiorespiratory fit-
ness (as defined by peak estimated metabolic equivalents
(METs)) was comparable to or greater than for
traditional CV risk factors.48 The current data support
that functional status has an equally important prognos-
tic role in patients with ESLD.
In a retrospective study of OLT candidates (n =
772) referred for screening SPECT at a single institu-
tion, only 8% of studies were deemed abnormal.49 A
total of 26 patients with positive SPECT and angio-
graphic evidence of CAD were denied transplantation;
however, CAD was the only factor for denial in only 7
patients. The analysis demonstrated that the screening
Figure 3. Kaplan–Meier curve for unadjusted cumulative survival from (A) cardiovascular death
and (B) all-cause death according to perfusion dichotomized by a summed stress score C 4. Two-
sided generalized Wilcoxon tests were used to determine significance.
Figure 4. Kaplan–Meier curve for unadjusted cumulative survival from (A) cardiovascular death
and (B) all-cause death according to functional capacity dichotomized by estimated METs B 4.
Two-sided generalized Wilcoxon tests were used to determine significance.
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stress MPI results were not associated with liver
transplantation eligibility and suggested that because
of the large number of competing factors considered
prior to transplantation and the low prevalence of
abnormal stress MPI results, screening for CAD should
be reserved for patients deemed otherwise acceptable for
transplantation. The higher prevalence of abnormal
SPECT perfusion in the current study suggests that
reserving screening to asymptomatic patients who are at
elevated baseline risk (unable to perform [ 4 METs,
presence of diabetes, smoking, renal dysfunction) is an
acceptable strategy and might increase the influence of
stress MPI findings.
Identifying advanced CAD in the form of
detectable CAC may offer an alternative strategy to
recognize vulnerable patients. Severe coronary artery
calcification (CACS [ 400 U) is predictive for revas-
cularization,50 and of 30-day post-LT cardiovascular
complications,39 although data supporting an increased
risk in OLT patients after the initial postoperative period
Figure 5. Kaplan–Meier curve for unadjusted cumulative survival from (A) cardiovascular death
and (B) all-cause death according to integrated results of SPECT and exercise capacity. Two-sided
generalized Wilcoxon tests were used to determine significance.
Figure 6. Annualized event rates for (A) cardiovascular death and (B) all-cause death according to
integrated results of SPECT and exercise capacity. (A) For each subgroup (number of CV deaths/
number of patients): METs C 4, normal perfusion (1/59); METs \4, normal perfusion (4/67);
METs C 4, abnormal perfusion (2/15); METS \4, abnormal perfusion (4/17). (B) For each
subgroup (number of all-cause deaths / number of patients): METs C 4, normal perfusion (15/60);
METs\4, normal perfusion (26/66); METs C 4, abnormal perfusion (2/15); METS\4, abnormal
perfusion (7/17).
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are lacking. Of concern, the current study demonstrates
that a minimal CACS in ESLD patients does not exclude
the possibility of finding abnormal perfusion on SPECT.
Furthermore, we found no association between CACS
and outcomes, although this study was not designed to
address this issue and was likely underpowered. The
presence of coronary atheroma per se is unlikely to be
the sole factor for excluding a patient from proceeding
to OLT. Increased CACS does not form an indication for
revascularization at any level and at present, a decision
to deny a patient transplantation driven by increased
CAC seems incorrect.
Although 10% of patients with minimal coronary
calcification had an abnormal SPECT result, only one
such patient suffered a major adverse cardiovascular
event (a sudden cardiac death) and there were no
adverse events in any patient with a CACS of zero after
a mean follow-up of 5 years. These findings support the
pragmatic approach recently proposed in this jour-
nal,51,52 where coronary computed tomography
angiography ± CACS can be used to exclude coronary
disease with the added advantage of having a long
warranty.
There are limitations to our study. These data are
from consecutive patients recruited from a single center.
The majority of patients were white males, which limits
the generalizability of the results. Given that roughly
half the cohort had diabetes, statin usage on study entry
was relatively low (22%) and although baseline medi-
cations were recorded, we did not capture information
on changes in medical therapy over the study period,
which is a factor that may have influenced outcomes. A
recent observational report suggested that so long as
patients were appropriately revascularized, the severity
or extent of CAD did not influence post-transplant
survival, although follow-up was limited to only 90
days.53 We are unable to provide information on the
influence of revascularization on OLT candidates
because of the low numbers of subjects who underwent
invasive coronary angiography. Our practice likely
reflects the conclusions drawn from general population
studies; randomized controlled trials have shown no
benefit in prophylactic revascularization compared with
medical therapy in stable patients undergoing surgery
(even major vascular surgery) despite the presence of
ischemia.54,55
CONCLUSION
These data suggest that MPI SPECT provides
incremental and independent prognostic value in OLT
candidates. Based on the presence of risk factors, it
appears reasonable to continue to risk stratify asymp-
tomatic candidates with a noninvasive assessment that
combines exercise testing and MPI SPECT imaging.
More prospective evidence is required, however, ideally
from randomized clinical trials, to guide the indications,
timing, and outcomes of revascularization therapy in
patients with ESLD.




HR (95% CI) P value
Age 0.95 (0.88–1.04) 0.272
Gender (female) 2.07 (0.56–7.64) 0.276
Diabetes 1.39 (0.87–7.59) 0.088
Current smoker 5.23 (1.07–25.46) 0.041
METs\4 2.73 (0.60–12.54) 0.196
Abnormal perfusiona 4.18 (1.43–12.27) 0.019
All variables listed were simultaneously entered into a
multivariate Cox regression model
METs, metabolic equivalents
aDefined as summed stress score C4
Figure 7. Incremental predictive value of exercise capacity
and stress SPECT results over clinical information to predict
cardiovascular death. The clinical data entered into the global
Chi-square analysis model included age, sex, diabetes, smok-
ing history. Abnormality on SPECT (defined as SSS C 4) and
exercise capacity (METs\4) were entered as binary variables.
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NEW KNOWLEDGE GAINED
Abnormal perfusion as defined by MPI SPECT, is
prevalent in the liver transplant population and an
independent predictor of cardiovascular death. MPI
SPECT provides complementary prognostic value to
functional testing—a combined assessment of cardiores-
piratory fitness and myocardial perfusion identifies those
subjects at highest risk of cardiovascular and all-cause
death.
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